Immix Biopharma, Inc. - Common Stock (IMMX)

IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024.

IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024.

IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Immix Biopharma Inc (NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T 

These best speculative stocks are the ones to buy in the long term for strong returns on your investment portfolio.

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for relapsed or refractory multiple myel

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.

Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.

Gainers